Acacia Pharma is a revenue stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.
Acacia Pharma’s portfolio comprises:
- BARHEMSYS®: FDA approved for the treatment and prophylaxis of postoperative nausea & vomiting (PONV) .
- BYFAVO™: FDA approved very rapid onset/offset benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy.
- APD403 (intravenous and oral amisulpride): a selective dopamine antagonist in Phase 2 for chemotherapy induced nausea & vomiting (CINV).
Acacia Pharma has its own commercial infrastructure in the US through which it will sell its products directly. Acacia Pharma was founded in 2007 and has offices in Cambridge, UK and Indianapolis, IN, USA. Acacia is listed on the Euronext Brussels exchange under ticker ACPH.
Gilde Healthcare acted as founding investor and supported Acacia as lead investor in all subsequent investment rounds including at IPO.